Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin
Authors:
- J. DollJDJ. Doll
- Y. WelkerYWY. Welker
- P. CacoubPCP. Cacoub
- S. PolSPS. Pol
- F. CarratFCF. Carrat
- F. Bani-SadrFBF. Bani-Sadr
- the ANRS HC02 – Ribavic Study teamTTthe ANRS HC02 – Ribavic Study team
- 1 September 2007
- journal article
- research article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 14 (9) , 639-644
Abstract
The most frequent and the most troublesome adverse effect of interferon plus ribavirin-based therapy is anaemia. The aim of this analysis was to determine the incidence and risk factors of anaemia (Hb < 10 g/dL) in human immunodeficiency virus/hepatitis C virus (HCV)-coinfected patients receiving anti-HCV therapy. We reviewed all cases of anaemia occurring among 416 patients participating in a randomized, controlled 48-week trial comparing peginterferon (peg-IFN) alpha 2b plus ribavirin with interferon alpha-2b plus ribavirin. Univariate and multivariate analyses were used to identify links with antiretroviral treatments, HCV therapy and clinical and laboratory findings. Sixty-one (15.9%) of the 383 patients who received at least one dose of anti-HCV treatment developed anaemia. In multivariate analysis the risk of anaemia was significantly associated with zidovudine (OR, 3.27 95% CI, 1.64-6.54, P = 0.0008) and peg-IFN (OR, 2.35; 95% CI, 1.16-4.57, P = 0.0179). The risk of anaemia was lower in patients with higher baseline haemoglobin levels (OR, 0.35 95% CI, 0.26-0.49, P < 0.0001) and in patients receiving protease inhibitor-based antiretroviral therapy (OR, 0.51 95% CI, 0.30-0.86, P = 0.0114). Zidovudine discontinuation could help to avoid anaemia associated with anti-HCV therapy.Keywords
This publication has 17 references indexed in Scilit:
- Early Monitoring of Ribavirin Plasma Concentrations May Predict Anemia and Early Virologic Response in HIV/Hepatitis C Virus-Coinfected PatientsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2005
- Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International PanelAIDS, 2005
- Pegylated Interferon Alfa-2b vs Standard Interferon Alfa-2b, Plus Ribavirin, for Chronic Hepatitis C in HIV-Infected PatientsA Randomized Controlled TrialJAMA, 2004
- Impact of Highly Active Antiretroviral Therapy on Anemia and Relationship Between Anemia and Survival in a Large Cohort of HIV-Infected WomenJAIDS Journal of Acquired Immune Deficiency Syndromes, 2004
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-Infected PatientsNew England Journal of Medicine, 2004
- Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon α-2b+ full-course vs. 16-week delayed ribavirinHepatology, 2004
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- Rapid suppression of hematopoiesis by standard or pegylated interferon-αGastroenterology, 2002
- Anemia in HIV-Infected Patients Receiving Highly Active Antiretroviral TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2002
- Inhibition of β-globin gene expression by 3′-azido-3′-deoxythymidine in human erythroid progenitor cellsAntiviral Research, 1999